Posted by Michael Wonder on 14 Jan 2016
Regorafenib in metastatic colorectal cancer: still only a hint of a minor additional benefit
4 January 2016 - After the expiry of the decision it made in 2014, the IQWIG has the reached same conclusion as Bayer did not present better clinical data.
For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/regorafenib-in-metastatic-colorectal-cancer-still-hint-of-minor-added-benefit.7124.html
